Phase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy (MSK-DA01) For Advanced Parkinson's Disease

  • sponsor
Updated on 13 September 2021


Dopamine neurons made from stem cells are injected into the brain under general anesthesia. Subjects then take medicines to partially suppress their immune system (aimed to prevent the body from rejecting the cells) for 1 year.

All subjects receive the treatment (i.e. there is no placebo group in this study).  Safety, tolerability, evidence of cell survival (using scans of the brain), and the effect on Parkinson's disease symptoms are assessed for 2 years post-transplant.


Condition Parkinson's disease
Clinical Study IdentifierTX278586
Last Modified on13 September 2021


Yes No Not Sure

Inclusion Criteria

Age 60-76 years old
Diagnosed with Parkinson’s Disease 5 to 15 years ago
Has complications of PD therapy such as wearing off and/or dyskinesia (slow uncontrolled writhing movements)
Able to participate in all study visits and evaluations including brain MRI and PET scans

Exclusion Criteria

Diagnosis of epilepsy, stroke, multiple sclerosis, Alzheimer’s disease or other serious brain diseases
Prior DBS, lesion therapy, or gene therapy for PD
Prior surgical or radiation therapy to the brain or spinal cord
Any medical condition resulting in high risk of immunosuppressive drugs, including any active infectious disease
Inability to temporarily stop anti-platelet agents or other anti-coagulant medications without serious risk
Previous or currently active malignant disease within the past 5 years, except basal cell carcinoma or in situ uterine cervical carcinoma that have been treated
Severe obesity (>350 lbs) or any condition that prevents use of PET/MRI
Pregnancy or breastfeeding
Contraindication to surgery or general anesthesia
Any other condition regarded as making subject unsuitable for trial. More detailed inclusion and exclusion criteria will be available from the study team
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note